Moderna CEO Says Its Cancer Vaccine Isn't a Disappointment, It's a Blockbuster — Barrons.com

What happened

Moderna CEO Stéphane Bancel defended the cancer-vaccine candidate intismeran autogene after Moderna's stock plunged 18% Thursday following a data leak. Trial data showed a 42% reduction in risk of recurrence or death in high-risk melanoma patients when combined with Merck's Keytruda versus Keytruda alone.

Confirmed

Global impact / market context

For investors, the gap between solid trial results and a sharp stock drop shows expectations, not just data, drive prices. A 42% risk reduction matters clinically, but investors may have priced in more, so future trial results in other cancers now carry heavy weight.

Analyst inference

The selloff suggests investors were buying on rumor and selling on news, and they may doubt whether melanoma results will repeat in other cancers. That uncertainty pressures Moderna's valuation and raises the bar for upcoming trial readouts, which the company needs to justify growth hopes.

Analyst inference

What to watch

1. Watch whether Moderna and Merck release fuller intismeran trial data, since Bancel says the data is the key focus and the leaked figures drove the 18% stock drop. Confirmed
2. Watch whether Moderna and Merck seek regulatory approval for intismeran in high-risk melanoma, a step that would turn trial results into a potential revenue-generating product. Proposed
3. Watch results from intismeran trials in other cancers, which remain unproven; success there could restore investor confidence, while weak results could extend the stock's decline. Analyst inference

Evidence

• Original source link unavailable